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Endothelin-1 receptor antagonist: Effects on endothelin- and cyclo-
sporin-treated mesangial cells. Endothelin- 1 (Et) has profound effects on
glomei-ular microcirculation and mesangial cell contraction. A parame-
ter of mesangial cell contraction was examined by measuring myosin
light chain phosphorylation (MLCP) in glomerular mesangial cells in the
presence and absence of a newly developed endothelin-l receptor
antagonist (Et). Addition of Et alone (10 nM) caused a marked increase
in MLCP, which, on average, rose by 53 6% above the level in cells
exposed to vehicle (P < 0.0005). This effect was shown to continue for
at least one hour; MLCP at 60 minutes was 64 12% higher than
controls, (P < 0.025), constituting a unique observation of an in vitro
parameter which parallels the characteristic in vivo effect of Et.
Treatment of cells with Et virtually abolished this Et-induced increase
in MLCP, which rose by only 2 3% and — I 4% for doses of Et of
44 fiM and 66 flM, respectively. Examination of the intracellular calcium
concentration, [Ca2], revealed that Et almost completely abolished
the transient increase in [Ca2] evoked by Et and also suppressed the
early portions of the sustained increase in [Ca2J. Et was ineffective in
abolishing [Ca2j1 increase in response to arginine vasopressin. Finally,
to evaluate Et's efficacy in a pathophysiologic setting, we also studied
mesangial cells exposed to cyclosporine (Cs). Exposure of mesangial
cells to Cs (l0- M) for 60 minutes caused a significant increase in
MLCP, on average, by 38 6% above control (P < 0.0005), while cells
exposed to Cs in the presence of Et increased MLCP significantly less,
by only 15 9%. These data provide further evidence for Et's
long-lasting cellular actions, and demonstrate inhibitory effects of an Et
receptor antagonist after direct cellular exposure to Et and also after Cs
exposure, a pathophysiologic setting which likely involves Et.
The magnitude and duration of vasoconstriction caused by
endothelin (Et) has earned it the reputation as the most power-
ful constrictor of mammalian tissue [1]. This characteristic, its
ubiquitous distribution in various cells and organs, and evi-
dence for its activation in conditions characterized by vasocon-
striction has led to the belief that it may be an important factor
in regulation of vascular tone in normal and disease states [2, 3].
Antagonism of Et's vasoconstrictor effects has been attempted
by various nonselective vasodilators with only inconsistent
results [4—6]. There has, therefore, been great interest in the
development of a specific antagonist of its actions such that
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many articles on the subject end with anticipation that a specific
antagonist will become available [7—9]. The quest for specific
antagonists of Et has been directed at inhibition of the putative
converting enzyme which converts the intermediate form of Et,
"big Et", to the mature Et, as well as antagonism of Et
receptors, Et and EtB [3, 10—12]. These subtypes differ in their
distribution and affinity for Et isoforms (EtA being specific for
Et-l, while EtB binds to all three isoforms). Although the
kidneys are well recognized to have high-affinity binding sites
[13, 14], it is of particular interest that glomerular mesangial
cells have most recently been shown to have both EtA and EtE
types of receptors [15]. Mesangial cells, which are widely
regarded as regulators of glomerular vascular tone [16], have
already been shown to respond to Et by decreasing planar
surface area [17, 18]. In the current studies, we examined
whether the effects of Et on mesangial cells can be modified by
a recently developed Et receptor antagonist. We also studied
the effects of this antagonist on cyclosporine-treated mesangial
cells, since Et is a likely participant in the renal vasoconstric-
tion in cyclosporine nephrotoxicity [2]. These studies utilize a
biochemical method for assessing myosin light chain phosphor-
ylation, previously shown by us and by others to permit
quantitation of mesangial cell contraction in response to a
variety of vasoactive substances [19, 20].
Methods
Chemicals
Endothelin-1 was purchased from Peptide International (Lou-
isville, Kentucky, USA); arginine vasopressin from Sigma
Chemical Co. (St. Louis, Missouri, USA); Fura-2 AM and
4-bromo-A23 187 were purchased from Molecular Probes (Eu-
gene, Oregon, USA). Anti-human platelet antiserum was a gift
from Dr. Kawamoto and Dr. Kelly of the National Institutes of
Health (Bethesda, Maryland, USA); and the endothelin recep-
tor antagonist was a gift from Banyu Pharmaceutical Co.
(Tokyo, Japan). This newly synthesized compound is an EtA
receptor selective antagonist, cyclo(-D-Trp-D-Asp-Pro-D-Val-
Leu-) MW 611, derived from the modification of a natural lead
of EtA [21, 22]. It has been shown to inhibit [125J] Et-1 binding
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to porcine aortic smooth muscle membranes (known to possess
EtA receptors) with an ICmax50 value of 22 nM [23].
Mesangial cell culture
Mesangial cells were isolated from glomeruli of rat kidneys as
previously described by us [20, 24]. Briefly, kidneys were
excised from male Sprague-Dawley rats weighing 100 to 150 g.
Cortical tissue was minced and passed through a series of
stainless steel sieves of decreasing pore sizes: 180, 106 and 75
m. The fraction accumulating on the 75 ,tm sieve was col-
lected in Hank's balanced salt solution buffered with 20 mvr
HEPES, pH 7.4 (buffered HBSS) and allowed to sediment by
gravity. The sedimentation step was repeated with buffered
HBSS three times. Microscopically, the glomeruli were shown
to be stripped of their capsules and virtually free of tubule
tissue. The glomeruli were treated with collagenase (1 mg/mI)
for 15 minutes and then plated onto 100-mm plastic tissue
culture plates maintained in RPMI-1640 supplemented with 17%
fetal bovine serum, penicillin 100 U/mI, streptomycin 100
g/ml, fungizone 0.25 sg/m1 at 37°C in 5% C02, and 95% air.
The cells were subcultured using trypsin/EDTA. Cells from
passages 3-10 were used in these experiments.
Assay of myosin light chain phosphorylation
Myosin light chain phosphorylation (MLCP) was assayed
according to the method previously reported by us with slight
modification [201. Sub-confluent mesarigial cells in 35 mm
dishes were deprived of serum for 24 hours. Cells were washed
twice with an isotonic solution (130 mri NaCI, 4.7 mr'i KCI, 1.2
mM MgCI2, 1.6mM CaCI2, 5 mM dextrose, and 20mM HEPES,
pH 7.4), and then incubated at 37°C for three hours in the same
isotonic solution with the addition of 25 Ci/ml of neutralized,
carrier-free [32PJ orthophosphate (Dupont Co., Wilmington,
Delaware, USA). Following a period of three hour incorpora-
tion of {32P1, 10 d of a test agent or vehicle in an isotonic
solution was added and incubation continued at 37°C. Each
experimental maneuver was performed in duplicate. The reac-
tion was stopped by freezing in ethanol at —70°C. Then an
extraction buffer was added containing 100 m sodium fluoride,
250 mr.i NaCI, 10mM EGTA, 5 mi EDTA, 1 mrvi phenylmethyl-
sulfonyl fluoride, 50 g/ml leupeptin, 8 mM sodium pyrophos-
phate, and 1% NP-40. The cells were extracted by rubber
policeman and centrifuged at 105,000 g for 20 minutes by
L2-65B ultracentrifuge (Beckman Instruments, Palo Alto, Cal-
ifornia, USA). The supernatant was incubated with human
anti-platelet myosin antibody at 4°C for 90 minutes. After an
additional incubation with standardized Staphylococcus aureus
(Pansorbin, Calbiochem, La Jolla, California, USA) at 4°C for
90 minutes, the mixture was sedimented by microcentrifugation
for five minutes. The pellet was then washed three times and
dissolved in SDS sample buffer consisting of 2% SDS, 10%
glycerol, 0.01% bromophenol blue, 62.5 mM Tris, pH 6.8, and
5% 2-mercaptoethanol. The mixture was boiled at 100°C for five
minutes and sedimented by microcentrifugation for five min-
utes. Each supernatant was subjected to SDS-PAGE in a 12%
acrylamide gel with 0.32% bisacrylamide using the discontinu-
ous buffer system of Laemmli [25]. After electrophoresis, gels
were stained, vacuum dried, and loaded in an X-ray cassette
with Kodak XR-5 X-ray film. Phosphorylated MLC was iden-
tified on the autoradiogram and its optical density (OD) was
measured by videodensitometry (Bio-Rad Laboratories, Rich-
mond, California, USA). The experimental OD value was
divided by the control OD value in each experiment and
expressed as percent of control.
Measurement of cytosolic Ca2 level
Cytosolic calcium [Ca2] levels were measured fluorometri-
cally using Fura-2 as previously reported by us [17]. Briefly,
mesangial cells were plated on glass coverslips and maintained
for four days in RPMI-1640; the cells were deprived of serum
for 24 hours prior to the experiment, then loaded with 5 to 10
ILM Fura-2 for one hour. Fluorescence was measured at 37°C
using continuous rapid alternating excitation (20 ms per read-
ing) from dual monochromators set at 340 and 380 nm, respec-
tively (Deltascan; Photon Technology mt., New Brunswick,
New Jersey, USA). The monochromators were coupled to an
inverted microscope using a 400 nm dichroic mirror and a lOx
Nikon-fluorescent oil immersion objective (numerical aperture
= 1.3). Fluorescent emission of greater then 435 nm was
measured by photon counting (type R928P; Hamamatsu Cor-
poration, Bridgewater, New Jersey, USA). At the beginning of
each experiment, background fluorescence was determined and
thereafter continuously subtracted from the emission reading.
The corrected fluorescent emission intensity ratio, using 340
and 380 nm excitation with background subtraction, was mon-
itored continuously in single cells. Baseline measurements were
performed during continuous perfusion with a solution contain-
ing 105 mM NaCl, 5 mM KCI, 25 mM NaHCO3, 10 mM
Na-acetate, 2.32 mr'r NaHPO4, 1,8 mrvi CaCl2, 1.0 mM MgSO4,
8 m glucose, 5 mt alanine, and 0.1% bovine albumin, pH
7.40. This solution was then substituted by one containing an
agonist with or without antagonist. At the end of each experi-
ment, the bath was changed to a zero calcium magnesium-free
solution. Perfusion buffer was modified further by the addition
of 4 mrvi EGTA and 16 sM 4-bromo-A23l87. After a stable
340/380 ratio was achieved (minimum, Rmin), the buffer was
changed back to the control bath, (1.5 m calcium) plus 5 M
4-bromo-A23 187, and the ratio was again allowed to stabilize
(maximum, Rmax). Intracellular calcium concentration was cal-
culated by: [Ca2 = Kd ({R — Rmin}/{Rmax — R}) (380mm!
38Omax) assuming the Kd for the Fura-2 Ca2 complex is 224 nM
at 37°C. The basal [Ca2] level is defined when the [Ca21i, level
becomes stable and the time zero denotes the time of addition of
agonist/antagonist. The calcium ratio unit is attained by deter-
mining the fold increase in [Ca2] value above the baseline.
Statistical analysis
Statistical analysis was performed by paired Student's t-test
or by analysis of variance followed by unpaired Student's t-test
as appropriate. Differences were considered significant at P <
0.05. Values are expressed as mean SE.
Results
Ejfrcts of endothelin-1 and endothelin receptor antagonist on
myosin light chain phosphorylation
The autoradiogram in Figure 1 shows the effects of endothe-
lin-1 (Et) and endothelin receptor antagonist (EtA) on MLCP in
cultured mesangial cells. Compared with vehicle (lanes I and 2),
addition of Et (10 nM) caused a dramatic increase in MLCP
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Fig. 1. Autoradiogram ofphosphorylated myosin light chain extracted
from cultured rat mesangial cells showing the effect of incubation (10
mm) of endothelin-1 (Et)(iO nM) with or without various concentrations
ofendothelin-1 receptor antagonist (EtA). Lanes 1 and 2: control cells;
lanes 3 and 4: Et; lanes 5 and 6: Et and Eç (22 nM); lanes 7 and 8: Et
and Et (44 nM). All lanes shown from same gel.
(lanes 3 and 4). MLCP increased in every experiment after Et
addition (N = 5) and, on average, was 53 6% above the
control value (Fig, 2, P < 0.0005). It was further shown that,
even 60 minutes after exposure to Et, MLCP was increased in
mesangial cells, on average, by 64 12% above vehicle
controls (N = 7, P < 0.0025). These data are in good agreement
with the well described vasoconstrictive actions of Et observed
in vivo and in vitro [26—29]. Figures 1 and 2 also depict the
effects of EtA. Endothelin receptor antagonist at 22 n signifi-
cantly dampened the Et induced-MLCP elevation (lanes 5 and
6) which, on average, rose only to 36 6% (N = 5; P < 0.025
vs. Et alone). Additionally, at 44 flM and 66 nM, EtA essentially
abolished the Et-induced MLCP, 2 3% (N =3; P < 0.005 vs.
Et alone) and —1 4%, respectively, (N 3; P < 0.005 vs. Et
alone). Since EtA at 44 nM essentially prevented Et-induced
increase in MLCP, this dose was used in all subsequent studies.
Changes of cytosolic Ca2* level evoked by Et with or without
EtA
Increased cytosolic Ca2 level, [Ca2I, is an integral com-
ponent in the mechanism of Et-mediated vasoconstriction and
consists of a rapid transient [Ca2]1 increase which lasts sec-
onds and a sustained phase which can last up to 20 minutes [30,
311. We, therefore, examined whether EtA modifies the well
described Et-induced patterns of [Ca2]1. Figure 3A shows the
[Ca2I increase evoked by 10 nM Et. The basal [Ca2I1 in
unstimulated mesangial cells was 116 12.9 nM (N = 37) which
is in good agreement with values reported by Menè, Simonson
and Dunn [32]. Peak [Ca2] increase, expressed as percent of
basal value, was 554 94% (N = 11), and is likewise compa-
rable to that found by others [30, 31]. Mesangial cell response to
Et added together with EtA is depicted in Figure 3B. EtA
completely abolished the transient increase in [Ca2]. In addi-
tion, EtA also appears to suppress the early portions of the
characteristic sustained [Ca2 increase.
The time averaged Ca2 waveforms evoked by three different
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Fig. 2. Densitometric analysis of myosin light chain phosphorylation
in mesangial cells in individual experiments following incubation with
endothelin-I (Et) with/without endothelin-i receptor antagonist (EtA).
Each point represents a mean of duplicate incubations. Horizontal lines
are the averaged values for each experimental maneuver.
experimental conditions using Et and EtA are shown in Figure 4,
where baseline Ca2 is taken to be 1.0 and the fold increase in
Ca2 is plotted on the vertical axis. Four upgoing arrows in
Figure 4 denote the different time points chosen for compari-
son. The maximum increase in [Ca2]1 occurred at an average
of 73 seconds after addition of Et (N = 11), having an average
ratio unit of 3.42 0.75 (P < 0.005 vs. baseline). EtA virtually
abolished the [Ca2]1 increase at this time. This inhibitory effect
of EtA on [Ca2 at 73 seconds occurred when EtA was added
simultaneously with Et (N = 7; ratio unit of 1.22 0.19 vs.
baseline 1.06 0.09, P = NS). The inhibitory effect of EtA on
was also observed in cells pretreated with EtA for two
minutes prior to the addition of Et (N = 5; ratio unit 1.10 0.21
vs. baseline 1.17 0.33). In contrast, 182 seconds following
exposure to Et, [Ca2]1 ratio unit was significantly reduced only
in the EtA pretreated group (1.32 0.37 vs. 2.74 0.45
following addition of Et alone and 1.99 0.49 in Et added
together with EtA). At 500 seconds after EtA exposure, there
was no significant difference between the EtA-treated groups
and group treated with Et alone.
We also assessed whether the blunted response in [Ca2]
following Et plus EtA reflects a delay in the appearance of the
transient phase. Since the transient phase of [Ca2I1 increase is
largely independent of extracellular Ca2 [30, 311, we compared
the calcium waveforms in a setting of extracellular calcium
depletion (100 nM).' We found that cells in the low calcium bath
exposed to Et/EtA had a similarly blunted calcium response to
Et (N = 3), as did the cells in normal calcium bath (1.5 mM)
described above, that is, 1.10 0.21 vs. 1.46 0.20 (P = NS).
Zero Ca2/EGTA bath could not be reliably used, since stable
baseline values were achieved inconsistently and cells were seen to
detach from the cover slips prior to the completion of the experiment.
For these studies, extracellular Ca2 was lowered to 100 flM, a value
slightly below resting mesangial cell [Ca2]1. In 100 n bath, we
achieved a stable baseline and cells remained attached to the coverslip.
Under these conditions, an increase in cell Ca2 in response to Et that
is above 100 n must represent intracellular Ca2 release.
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Fig. 4. Averaged intracellular calcium waveforms evoked by endothe-
lin (El) and endothelin receptor antagonist (EtA). Baseline Ca2* is 1.0
and the fold increase is plotted on the vertical axis. Et was added at time
zero is all groups. Et (N = 11); Ft added together with Et (N = 7);
Ft/EtA added 2 minutes after pretreatment with EtA (N = 5).
Furthermore, the appearance of the [Ca211 peak occurred at 87
6 seconds, which is similar to the peak in a normal calcium
bath of 73 seconds, and also to the appearance of the peak time
in cells in a low calcium bath exposed to Et alone, such as, 75
7 seconds (P = NS). Since extracellular Ca2 is less than
intracellular Ca2, this Ca2 concentration increase likely re-
flects intracellular Ca2 release as reported by others [30, 31].
The specificity of EtA's effect was evaluated with another
potent constrictor of rnesangial cells, namely, arginine vaso-
pressin (AVP). AVP is known to cause contraction of mesangial
cells and also to increase cytosolic Ca2 [20, 33, 34]. In the
current study, AVP (100 nM) caused a marked increase in Ca2,
3.15 1.13 times baseline values (N 6), which was not
statistically different from the response when the same AVP
Cyclosporine Cyclosporine/Et
Fig. S. Densitometric analysis of myosin light chain phosphorylation
in mesangial cells of individual experiments following incubation with
cyclosporine with/without endothelin-1 receptor antagonist (EtA). Each
point represents a mean of duplicate incubations. Horizontal lines are
the averaged values for each experimental maneuver.
dose was added together with EtA (44 nM), 4.40 1.26 (N = 4,
P = NS).
Effect of cyclosporine with or without Et4 on MLCP
Since cyclosporine-induced renal vasoconstriction is, at least
in part, dependent on Et [7, 35], we also exposed rat cultured
mesangial cells to cyclosporine (Cs) l0 M for 60 minutes.
Figure 5 demonstrates that Cs significantly enhanced MLCP by
38 6% (N = 6, P < 0.0005) compared with vehicle-treated
controls. The volume of vehicle added to the control cells was
identical to Cs. In these studies, pretreatment with EtA for two
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Fig. 3. (A) Intracellular calcium waveform of an individual experiment following addition of endothelin-1 (El). (13) Intracellular calcium waveform
following addition of Et and endothelin-l receptor antagonist (EtA) (44 nM).
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minutes followed by exposure to Cs, as described above,
significantly suppressed MLCP increase to only 15 9% (N =
6, P < 0.025 vs. Cs alone).
Discussion
Assessment of myosin light chain phosphorylation has been
extensively used to study the regulatory mechanisms in smooth
muscle cell contraction [36, 37]. Rembold and Murphy demon-
strated that endothelin or histamine-induced MLCP correlates
well with active stress and/or shortening velocity in porcine
arterial smooth muscles [38]. Similarly, Adams et al [39] de-
scribe that MLCP closely parallels muscle tension generated
following several vasoconstrictors including endothelin. Recent
physiologic correlates of MLCP in smooth muscle cells have
been shown to include development of tension or increase in the
maximal tension velocity which reflect attachment of cross
bridges [36, 37]. Glomerular mesangial cells have long been
recognized to possess features akin to smooth muscle cells
(actin and myosin, cytoskeletal scaffolding, receptors for vaso-
active substances, and contraction in response to these vaso-
active substances) [321; these smooth muscle cell-like features
have been proposed to contribute importantly to the regulation
of renal microcirculatory hemodynamics [l6—201. However,
thus far, few studies have examined mesangial cell function
using MLCP [19, 20]. We have previously shown that the
contractile mechanisms of mesangial cells are conserved and
that agonists which are well known to modulate renal cortical
hemodynamics, such as angiotensin II, arginine vasopressin,
and endothelin, increase MLCP in parallel with observed
changes in [Ca2] and morphological expression of contraction
[20]. The present data reiterate the idea that phosphorylation of
myosin light chain in cultured mesangial cells increases drama-
tically in response to endothelin (10 nM). In addition, this study
found that this Et-induced enhancement in MLCP persists for at
least 60 minutes and that the magnitude of the response
continues. These findings of a persistent in vitro biochemical
response to Et correspond with the numerous in vivo studies
which show that the Et-indüced vascular contraction lasts for
over an hour [26, 27]. Previously there have been few enduring
cellular markers of this remarkable in vivo effect of Et. Thus,
Simonson and Dunn [18] showed that decreased planar cross
sectional area, which is taken as a marker of mesangial cell
contraction, persists for some 30 minutes following Et, using
some tenfold higher Et dose than the current study. The
magnitude and particularly the duration of the Et-induced
vasoconstriction have been proposed to play a role in physio-
logic and certain pathophysiologic settings, but documentation
of a pathophysiologic role for Et has been hampered by the lack
of specific antagonists of its actions. We used the newly
developed antagonist of Et receptor to study Et's effect on the
contraction of mesangial cells. As shown in Figures 2 and 3, EtA
inhibited Et-induced stimulation in MLCP. While 22 nM EtA
decreased Et-induced rise in MLCP by some 30%, higher
concentrations of EtA (44 and 66 nM) virtually abolished the
cellular response to Et. Although not shown, EtA alone caused
a small (<10%) increase in MLCP in mesangial cells. This
parallels the partial agonist effects recently described for an-
other Et receptor antagonist [40], as well as receptor antago-
nists for other agents [41].
Et causes a characteristic effect on intracellular calcium in
mesangial cells, whereby both the amplitude and duration of
[Ca2] increase exceed any other agonist [31, 32, 42]. When we
examined the effects of EtA on [Ca2] in mesangial cells, we
found that EtA (44 nM) virtually abolished the transient [Ca2]1
increase (Fig. 3B). In contrast, EtA was not effective in sup-
pressing the well described increase in [Ca211 evoked by
arginine vasopressin [34]. In view of previous findings that
mesangial cells retain receptors for both AVP and Et over
numerous passages [15, 43], these findings point to the specific
nature of the Et receptor antagonist. EtA suppressed the [Ca2 ]
increase regardless of whether it was added two minutes prior
to or concurrently with Et. This suppression was most pro-
nounced in the initial two minutes (Fig. 4); after three minutes,
only the EtA pretreated cells had persistent [Ca2] suppression.
This tendency for lower [Ca2] in the EtA-treated cells (partic-
ularly when EtA was added before exposure to Et) continued for
some four to five minutes. Since the transient phase reflects
largely intracellular mobilization of calcium, the suppressive
effects of EtA may represent reduced activation of phospholi-
pase C and subsequent inositol phosphate turnover associated
with this phase [17, 30, 31]. The long-lasting, sustained phase of
Et-induced increase in [Ca2] is composed largely of extracel-
lular calcium influx [30, 31]. To ascertain whether the late
[Ca2], increase in EtA-treated cells represents a blunted or
delayed intracellular Ca2 release, we repeated the Et/EtA
studies in 100 nM extracellular calcium. We found that cells in
the low calcium bath exposed to Et/EtA had a blunted calcium
response to Et similar to the cells in normal calcium bath, and
the appearance of the [Ca2I peak occurred at a similar time
point. These data suggest that EtA primarily affects the release
of Ca2 from intracellular stores. However, since some of the
initial surge in [Ca2] may represent the sustained increase
[Ca2J phase, it is possible that EtA also blunts the initial
portions of the sustained phase (Fig. 4).
Although there are no significant differences in [Ca2]1 at or
beyond four minutes of incubation with Et plus EtA, EtA
drastically reduces Et increase in MLCP at 10 minutes. This
apparent divergence may be related to the following possibility,
namely that the increase in MLCP at 10 minutes may be more
closely associated with mechanisms activated by the transient
calcium mobilization. In this regard, the only other study which
attempts to correlate [Ca2]1 and MLCP was performed using
AVP in cultured hepatocytes [44]. In that study, cytosolic
calcium spike and increase in MLCP occurred within seconds
of addition of AVP; importantly, however, MLCP increase
peaked after the calcium spike and, similar to our study,
persisted minutes longer than the calcium spike, well into the
plateau phase of calcium increase. It is of interest that in our
studies, the waveform evoked by Et plus EtA is reminiscent of
the monophasic pattern caused by low concentrations of Et (1
to 10 pM) [30, 31]. Furthermore, the calcium ratio units in the
present study are similar to those previously reported for Et 
10 p, which were not associated with identifiable functional!
biochemical parameters such as reduction in the cross sectional
area of mesangial cells, inositol phosphate turnover, cytosolic
alkalinization, or thymidine incorporation [17, 30, 31]. These
results are consistent with those of Simonson and Dunn [18]
who showed that Et-1-induced mesangial cell contraction is
mediated by a Ca2 signaling system activated by phospholi-
pase C. It is not clear at the present time whether the marked
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and persistent increase in the MLCP observed at 60 minutes
relates to the changes in [Ca2], or other mechanisms such as
persistent activation of protein kinase C, previously linked to
the long-lasting actions of Et [45]. The activation of protein
kinase C may be by Et-stimulated phosphotidylcholine hydrol-
ysis by phospholipase C and/or phospholipase D [17, 31, 46].
The apparent persistence of Et's effects in mesangial cells
provided the impetus for exploring whether pathophysiologic
conditions can also be examined with this technique. This
seemed especially relevant, since renal vasoconstriction follow-
ing cyclosporine is, at least in part, believed to be dependent on
Et [7, 35, 471. Thus, in vivo, cyclosporine causes a prompt,
although transient, elevation in circulating Et, as well as up
regulation of glonierular endothelin receptors; furthermore,
infusion of anti-endothelin antibody relieves the glomerular
vasoconstriction. In the current study, addition of Cs l0— M to
glomerular mesangial cells caused a marked increase in MLCP
measured 60 minutes after addition of the drug (Fig. 5). This
finding confirms previous reports which describe a decrease in
mesangial cell cross sectional area in response to cyclosporine
[48]. Lower doses of Cs did not reproducibly increase MLCP,
which is interesting since l0 M, but not lower doses of Cs,
increase production of endothelin by renal epithelial cell lines
[49]. Previous study of Cs effects on endothelial cells used IO
M to approximate plasma levels in patients on oraL/intravenous
treatment found morphological changes, decreased cell replica-
tion and increased PGI2 synthesis but no decrease in cell
viability [SO], However, a higher dose of Cs may be relevant in
studies of mesangial cells since it is now known that tissue
levels of Cs (including those within the kidney) are higher than
in blood or plasma [511. The present study also found that
addition of EtA with cyclosporine significantly ameliorates this
contractile response. In this regard it is of interest that Lanese,
Schrier and Conger recently reported preliminary data that the
same receptor antagonist abolishes vasoconstriction of isolated
renal arterioles caused by cyclosporine [52]. In addition, this
receptor antagonist was found to be protective in preserving
glomerular filtration and tubule function in a model of ischemic
damage in isolated kidneys [53].
The mechanisms for the intriguing observations in our studies
may include antagonism of Et elaborated by the cyclosporine
treated mesangial cells. That mesangial cells elaborate Et is
now established [54]. In addition, cyclosporine has been shown
to promote Et production by a variety of cells including a renal
cell line [49]. Thus, it is possible that EtA antagonizes the
endogenously produced Et in mesangial cells. It must be
underscored that there are several other mediators which have
been implicated in toxicity associated with cyclosporine, in-
cluding vasoconstricting thromboxane A2 and platelet activat-
ing factor, among others [55]. Our observations that EtA ame-
liorated but did not completely abolish the increase in MLCP
following exposure to Cs suggest that other factors besides Et
or synergistic effects between Et and other agents contribute to
cyclosporine-induced cellular contraction/renal vasoconstric-
tion. It should further be noted that, although activation of Et
by cyclosporine appears well documented in various in vivo and
in vitro settings [2, 7, 8, 35, 48, 52], it is not at all clear what the
functionally relevant level of Et is in pathophysiologic settings
[2]. For this reason, it is especially pertinent to apply the
specific Et antagonist to study these functional effects.
In this report, we demonstrate a marked endothelin-induced
increase in mesangial cell myosin light chain phosphorylation, a
parameter reflecting cellular contraction. In addition, we show,
for the first time, that this effect persists within these cells and
parallels the well described in vivo vasoconstriction following
exposure to endothelin. The endothelin-induced increase in
mesangial cell myosin light chain phosphorylation can be sup-
pressed with the endothelin receptor antagonist. This response
is associated with the inhibition of the transient, but not the
sustained, increase in intracellular calcium. In the pathophysi-
ologic setting of cyclosporine exposure, which by itself causes
a significant increase in myosin light chain phosphorylation,
endothelin receptor antagonist is effective in abating this effect,
further supporting an important role for Et in physiologic and
pathophysiologic vasoconstriction.
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